Acute retinal arterial occlusion after intravenous administration of bevacizumab

Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endoth...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2009-05, Vol.2009 (may17 1), p.bcr0120091478-bcr0120091478
Main Authors: Artunay, Ozgur, Yuzbasioglu, Erdal, Rasier, Rifat, Sengul, Alper, Bahcecioglu, Halil
Format: Article
Language:English
Subjects:
Cancer therapies
Cardiovascular disease
Chemotherapy
Defects
Europe (East)
Health risk assessment
Lung cancer
Male
Medical personnel
Patients
Studies
Thromboembolism
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Vascular endothelial growth factor
White
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumour angiogenesis, the formation of new blood vessels to the tumour. The use of bevacizumab has spread worldwide, but the drug related adverse events associated with its use have been reported in a few retrospective reviews. We report on a previously unpublished case of retinal artery occlusion following the use of systemic bevacizumab.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr.01.2009.1478